Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
19,450
-600 (-2.99%)
Jan 19, 2026, 3:30 PM KST
413.53%
Market Cap865.33B
Revenue (ttm)46.65B
Net Income (ttm)16.75B
Shares Out44.49M
EPS (ttm)1,513.84
PE Ratio12.85
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume645,053
Average Volume2,723,744
Open20,000
Previous Close20,050
Day's Range19,000 - 20,100
52-Week Range3,138 - 26,600
Betan/a
RSI49.37
Earnings DateMar 13, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.